Anorexia Nervosa: The Hormonal Link to Relapse and Recovery
Anorexia nervosa, a severe and life-threatening eating disorder, has long been a challenging condition to treat. While doctors can address nutritional deficiencies and psychologists can tackle underlying thought patterns, the high relapse rates among hospitalized patients remain a pressing concern. A recent study published in Translational Psychiatry has shed light on a potential hormonal mechanism that may contribute to these relapses, offering new insights into the disorder's complexities.
The research, led by neuroscientist Virginie Tolle, focuses on the hormone ghrelin and its interaction with a ghrelin antagonist called LEAP2 (liver-expressed antimicrobial peptide 2). Tolle's findings, presented at the Federation of European Neuroscience Societies Forum 2026, suggest that an imbalance in these hormones may play a crucial role in the relapse cycles associated with anorexia nervosa.
Tolle's study involved 30 women diagnosed with anorexia nervosa, aged 18 to 60, who were undergoing refeeding treatment at a specialized eating disorders center. Blood samples were collected before and after treatment, as well as six months later. The researchers found that LEAP2 levels were significantly higher in patients upon hospitalization, decreasing during weight restoration, and then rising again when patients relapsed.
The ghrelin/LEAP2 ratio, according to Tolle, is a critical indicator of impulse control. In patients who maintained stable weight gain after discharge, this ratio was negatively correlated with impulse control. However, in those who relapsed, LEAP2 levels returned to higher levels, suggesting a potential link between hormone imbalance and the impulsive behaviors that contribute to relapse.
To further explore this hormonal connection, Tolle and her team conducted experiments on mice that had lost a quarter of their body weight. These mice exhibited increased impulsivity when offered an immediate food reward, a behavior that only partially subsided with refeeding. Higher LEAP2 levels were strongly correlated with persistent impulsive behaviors, supporting the hypothesis that an imbalance in ghrelin and LEAP2 may contribute to the dangerous relapse cycles in anorexia nervosa.
The implications of these findings are profound. If replicated in a larger human sample, blood tests for LEAP2 levels could potentially identify patients at risk of relapse before it occurs. This could enable earlier intervention and more personalized treatment strategies.
Moreover, the discovery of LEAP2 as a biomarker of relapse opens up exciting possibilities for pharmacological treatments. By targeting this hormone, researchers may be able to catalyze the shift towards full recovery, addressing the metabolic and cognitive consequences of food restriction in anorexia nervosa.
Tolle emphasizes the significance of these findings, stating, 'Metabolic signals that normally regulate hunger adapt differently in pathological eating, such as anorexia nervosa. These signals also influence the brain and decision-making processes.' The research highlights the potential of LEAP2 as a therapeutic target and a biomarker, paving the way for more effective and personalized treatments for anorexia nervosa.
In conclusion, this study provides a fascinating glimpse into the hormonal underpinnings of anorexia nervosa, offering a potential explanation for the challenges of recovery and relapse. As Tolle and her colleagues continue to explore these findings, the hope is that they will lead to improved treatment strategies and a better understanding of this complex disorder.
